Establishment of an antibody specific for AMIGO2 improves immunohistochemical evaluation of liver metastases and clinical outcomes in patients with colorectal cancer

Table 1 AMIGO2 expression and clinicopathological factors affecting overall survival rate in 173 CRC patients

Variables	Total (n)	AMIGO2 expression		p value
Variables	Total (n)	Low (n = 124)	High (n = 49)	p value
Age (years)
< 70	87	64 (74%)	23 (26%)	0.580
≥ 70	86	60 (70%)	26 (30%)	0.580
Sex
male	95	66 (70%)	29 (30%)	0.478
female	78	58 (74%)	20 (26%)	0.478
Tumor location
colon	122	89 (73%)	33 (27%)	0.565
rectum	51	35 (69%)	16 (31%)	0.565
Tumor size
< 4.0 cm	68	47 (69%)	21 (31%)	0.548
≥ 4.0 cm	105	77 (73%)	28 (27%)	0.548
Histological grade
differentiated type^a	157	110 (70%)	47 (30%)	0.115
undifferentiated type^b	16	14 (88%)	2 (12%)	0.115
Depth of invasion^c
T1/2	11	7 (64%)	4 (36%)	0.380
T3/4	162	117 (72%)	45 (28%)	0.380
Lymph node metastasis
absent	90	70 (78%)	20 (22%)	0.064
present	83	54 (65%)	29 (35%)	0.064
Lymphatic invasion^d
ly0/1	65	48 (74%)	17 (26%)	0.623
ly2/3	108	76 (70%)	32 (30%)	0.623
Vascular invasion^e
v0/1	97	75 (77%)	22 (23%)	0.050
v2/3	76	49 (65%)	27 (35%)	0.050

^aWell- and moderately differentiated adenocarcinoma
^bPoorly differentiated adenocarcinoma, signet ring cell carcinoma, and mucinous carcinoma
^cT1, lamina propria or submucosa invasion; T2, muscularis propria invasion; T3, subserosa invasion or within adventitia; T4, serosa penetration or adjacent organ invasion
^dly0, no invasion; ly1, minimal invasion; ly2, moderate invasion; ly3, severe invasion
^ev0, no invasion; v1, minimal invasion; v2, moderate invasion; v3, severe invasion

ISSN: 1746-1596